EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis

Haixia Zhang, Jiaqiang Hu, Yaxi Jiang, Lihua Deng, Song Liu

Frontiers in Oncology · 16.06.2026 · 16

DOI: 10.3389/fonc.2026.1853205 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 16.06.2026. Verfasst von Haixia Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sichuan University West China Hospital Guang'an Hospital, Guang'an, Sichuan, China. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The comparative efficacy of pharmacological treatments for lower-risk myelodysplastic syndromes (LR-MDS) remains uncertain because head-to-head randomised evidence is limited.

Methods

We performed a systematic review and network meta-analysis of randomised controlled trials evaluating pharmacological treatments for LR-MDS. Outcomes of interest were haematological improvement–erythroid (HI–E), red blood cell transfusion independence (RBC–TI), haematological improvement–platelet (HI–P), and adverse events (AEs).

Results

We included 20 trials (2,877 participants), of which 17 trials (2,670 participants) contributed to connected treatment networks. For HI–E, luspatercept and ESA-based regimens were associated with higher rates. Lenalidomide-containing regimens showed favourable RBC–TI outcomes, including lenalidomide plus ESA, lenalidomide with or without ESA and/or G-CSF, and lenalidomide monotherapy. For HI–P, eltrombopag and romiplostim showed potential benefits. Safety profiles differed across treatments: CC-486 and imetelstat were associated with higher odds of neutropenia and gastrointestinal toxicity, whereas luspatercept was associated with increased fatigue and AEs.

Conclusion

Comparative treatment benefit in LR-MDS differs by clinical endpoint. These findings support an individualised, goal-directed treatment approach rather than a single universally superior therapy. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420251184384.

Schlagwörter

Stichwörter der Autor:innen

erythroid responselower-risk myelodysplastic syndromesnetwork meta-analysispharmacological treatmenttransfusion independence

Autor:innen und Institutionen

  • Department of Pharmacy, Sichuan University West China Hospital Guang'an Hospital, Guang'an, Sichuan, China.
  • Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.

Zitieren

APA

Zhang, H., Hu, J., Jiang, Y., Deng, L., & Liu, S. (2026). Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1853205

Vancouver

Zhang H, Hu J, Jiang Y, Deng L, Liu S. Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1853205

BibTeX
@article{Zhang2026,
  author = {Zhang, Haixia and Hu, Jiaqiang and Jiang, Yaxi and Deng, Lihua and Liu, Song},
  title = {Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1853205}
}
Kostenlos starten →